Front Page News
Cure SMA Publishes Update on the Birth Prevalence of Spinal Muscular Atrophy (SMA)
Cure SMA is pleased to announce the publication of “Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US” in JAMA Pediatrics on […]
Read More ›Special Session Highlights from 2024 Annual SMA Research & Clinical Care Meeting
Each year, Cure SMA collaborates with our Scientific Advisory Board to plan a Special Session to be held during the Annual Research & Clinical Care […]
Read More ›Congressional Action Recognizes Unmet Needs of SMA Community
This week, a key congressional committee recognized the unmet, everyday living needs of individuals with spinal muscular atrophy (SMA) by urging the National Institutes of […]
Read More ›SMA Highlights: Updates from Biogen
On July 12, 2024, Biogen shared highlights and updates from the 2024 Annual SMA Conference, including their collaboration with Delta Flight Products and their sponsorship […]
Read More ›Clinical Research and Drug Development Session Highlights from 2024 Annual SMA Research & Clinical Care Meeting
During the first week of June, SMA researchers and clinicians from around the world met in Austin, Texas, for the 28th Annual SMA Research & […]
Read More ›Spring 2024 Issue of Compass Now Available
The Spring 2024 issue of Compass is now available online. This year, we are proud to announce six new research grants, totaling $750,000, to […]
Read More ›Thank You for an Amazing 2024 Annual SMA Conference!
Thank you to everyone who attended the 2024 Annual SMA Conference at the JW Marriott in Austin, Texas! It was an impactful weekend of opportunities […]
Read More ›SMA Researchers and Clinicians from Around the World Gather at the 28th Annual SMA Research & Clinical Care Meeting
During the first week of June, SMA researchers and clinicians from around the world met in Austin, Texas, for the 28th Annual SMA Research & […]
Read More ›Cure SMA Announces Additional $750,000 in Basic Research Funding
At the Annual SMA Research and Clinical Care Meeting, Cure SMA highlighted six new basic research grants totalling $750,000. Cure SMA also announced another $750,000 […]
Read More ›Five-Year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of SMA Achieved or Maintained the Ability to Sit, Stand or Walk
Summary of Data Presented After 5 years of treatment, 91% of children were alive – without treatment, children with Type 1 SMA would not be […]
Read More ›